Related Experiment Video
Updated: Dec 7, 2025

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
Published on: July 4, 2007
Tocilizumab-induced Leukoencephalopathy with a Reversible Clinical Course
Ryo Sasaki1, Nozomi Hishikawa1, Emi Nomura1
1Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan.
Tocilizumab (TCZ) can cause leukoencephalopathy, a brain condition, after long-term use in rheumatoid arthritis patients. Early discontinuation of TCZ improved cognitive function and brain imaging in a reported case.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Tocilizumab (TCZ) is an interleukin-6 receptor antagonist used for autoimmune diseases like rheumatoid arthritis (RA).
- Long-term safety data for TCZ, particularly regarding neurological effects, requires ongoing investigation.
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Acute Pancreatitis II: Clinical Manifestations and Management
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...

